Press Releases NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 03:27:52 2026-02-09 pm EST			5-day change	1st Jan Change
10.01 ^USD	-1.28%		-18.58%	-23.24%

Jan. 14	NovoCure Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:45 AM
Jan. 12	NovoCure Reports Rise in Q4 Preliminary Revenue	MT

Press Releases

Jan. 12	Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update	BU
Dec. 22	Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference	BU
Dec. 01	Novocure Appoints Company President Frank Leonard as Chief Executive Officer	BU
Nov. 26	Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference	BU
Nov. 12	Novocure to Participate in 2025 Jefferies Global Healthcare Conference	BU
25-10-30	NovoCure: Q3 Earnings Snapshot	AQ
25-10-30	Novocure Reports Third Quarter 2025 Financial Results	BU
25-10-16	Novocure to Present New Research for Tumor Treating Fields Therapy at European Association of Neuro-Oncology Meeting and the European Society for Medical Oncology Congress	AQ
25-10-15	Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress	BU
25-10-01	Novocure to Report Third Quarter 2025 Financial Results	BU
25-09-29	Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting	BU
25-09-15	Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)	BU
25-08-28	Novocure Announces Upcoming Investor Events	BU
25-08-25	Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain	BU
25-08-20	Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer	BU
25-07-25	NovoCure: Q2 Earnings Snapshot	AQ
25-07-24	Novocure Reports Second Quarter 2025 Financial Results	BU
25-07-01	Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025	BU
25-06-30	Novocure to Report Second Quarter 2025 Financial Results	BU
25-05-31	Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting	BU
25-05-27	Novocure Announces Upcoming Investor Events	BU
25-04-24	NovoCure: Q1 Earnings Snapshot	AQ
25-04-24	Novocure Reports First Quarter 2025 Financial Results	BU
25-04-23	Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting	BU
25-04-22	Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Press Releases

Filters